November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

Roche Secures Two FDA Approvals for Oncology and Immunology Treatments

🏢 Companies 2 min read 👁 1

Swiss pharmaceutical giant Roche Holdings saw its shares slip 0.70% to $60.52 following the green light from regulators for new therapies targeting breast cancer and chronic kidney disease.

Roche Secures Two FDA Approvals for Oncology and Immunology Treatments🏢Companies

Photo: Benzinga

Key points

  • Wilserdly approved with everolimus for advanced breast cancer
  • Gazyva cleared as first treatment for primary membranous nephropathy
  • Roche shares fell 0.70% to $60.52 following the announcement

Swiss drug manufacturer Roche Holdings announced that federal regulators cleared a pair of new treatments spanning its oncology and immunology divisions. The updates include a green light for an advanced breast cancer regimen and a first-of-its-kind therapy for a severe autoimmune kidney condition. Despite the positive regulatory updates, shares of the pharmaceutical company dipped 0.70% to trade at $60.52, hovering near a 52-week peak of $61.75.

The first regulatory nod covers Wilserdly, an oral combination treatment paired with everolimus, intended for adult patients dealing with specific advanced or metastatic breast cancers driven by genetic mutations. Clinical trial data showed this all-oral approach cut the likelihood of disease progression or mortality by 62% compared to standard endocrine care. Additionally, regulators accepted a priority filing for the drug as an early-stage adjuvant therapy, with a decision expected by late November 2026.

Separately, the agency cleared Gazyva for adult patients suffering from primary membranous nephropathy, a progressive autoimmune disorder that can lead to organ failure. Phase 3 trial data demonstrated that over a third of participants achieved complete remission of proteinuria at 104 weeks, significantly outperforming alternative treatments. This milestone represents the initial approved therapy specifically for this condition, alongside existing indications for the drug in other immune-driven renal diseases.

What to watch next: Monitor upcoming regulatory milestones, including the targeted late-2026 decisions for early-stage breast cancer and systemic lupus erythematosus applications.

Source Benzinga — benzinga.com/news/fda/26/11/63362115/roche-wins-dual-fda-approvals-… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.